Siemens Aktiengesellschaft · XETR:SIE
Siemens Aktiengesellschaft — Siemens — Investor Day (September 2009)
29 slides from Siemens Aktiengesellschaft's investor day presentation, Sep 29, 2009
Slide 1: Siemens Healthcare Workflow & Solutions Division
Siemens Healthcare Workflow & Solutions Division Thomas Miller CEO Workflow & Solutions Division Capital Market Day Siemens Healthcare London, September 29, 2009 © Siemens AG 2009. All rights reserved.
Slide 2: Safe Harbour Statement
Safe Harbour Statement This document contains forward-looking statements and information – that is, statements related to future, not past, events. These statements may be identified by words such as “expects,” “looks forward to,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,”
Slide 3: Siemens Healthcare Workflow & Solutions Key data FY 2008
Siemens Healthcare Workflow & Solutions Key data FY 2008: Revenue: €1.5bn Underlying margin: 9.9% Employees: ~ 7,200 R&D: ~ €100m © Siemens AG 2009. All rights reserved. Page 3 Sept. 29, 2009 Capital Market Day Healthcare Healthcare Workflow & Solutions
Slide 4: Our products are 'closest to the patient' and services are 'closest to the customer'
Our products are 'closest to the patient' and services are 'closest to the customer' for the Sector Innovative solutions Cross-Sector management driving revenue focused on patient care to divisions Customer Services Radiation Oncology Total Lifecycle Solution for installed base drives revenue to Ima
Slide 5: Oncology: Focusing on the complete continuum of care
Oncology: Focusing on the complete continuum of care 82 cm recon FOV Cancer will be- 50 cm FOV come the leading cause of death Detect early Treat individually globally in 2010 Screening Precise Radiation Blood tests Therapy delivery Cancer rates Customized medical doubled from oncology f
Slide 6: The radiation oncology market is not impacted as highly by economic and political changes
The radiation oncology market is not impacted as highly by economic and political changes Portfolio Market trends Radiation Therapy Market: > €2.3bn by 2015 In 2010, U.S. market: €500m German market: €137m 50% of cancer patients receive radiation therapy Siemens holds approximately 25% of th
Slide 7: Taking action in Particle Therapy
Taking action in Particle Therapy On the frontiers of medicine Challenges Encountered significant technical and engineering challenges associated with cutting-edge technology Software development challenges leading to project delays Collapse of accelerator supplier Life saving technology Takin
Slide 8: Women's Health: Investing in innovation in a growing market
Women's Health: Investing in innovation in a growing market Advanced screening and diagnostics Market trends finds disease earlier Growth: 1.5 million new cases in 2010 Mortality decreases attributed to screening Strongest growth in emerging markets India: >50% of women have advanced cancer
Slide 9: Surgical Market: 10% annual procedure growth
Surgical Market: 10% annual procedure growth ARCADIS Orbic C-arm Market trends 10% annual procedure growth driven by aging population and trend for minimally invasive orthopedic surgery 1,000,000 knee, hip, shoulder replacements annually 6,000,000 spine surgeries 2,000,000 for trauma (U.S. o
Slide 10: Audiology: A strong market-leading business
Audiology: A strong market-leading business Differentiated product offering Untapped market potential High volume market with attractive sustainable growth rates Significant opportunity due to low market penetration 71 million adults in Europe, 30 million in North America have hearing loss O
Slide 11: Workflow & Solutions: Overview of financial performance
Workflow & Solutions: Overview of financial performance Orders Revenue €m +9% €m 0% 1) -3% +3% (+14% ) (+5%1)) (-5%1)) (+1%1)) 1,522 1,653 1,494 1,490 1,203 1,169 1,083 1,118 Book- to-bill 1.02 1.11 1.11 1.05 FY 2007 FY 2008 Q3 YTD Q3 YTD FY 2007 FY 2008 Q3 YTD Q3 YTD FY 2008 FY 2009 FY 2008 FY 2009
Slide 12: We have addressed our challenges in FY 2009
We have addressed our challenges in FY 2009 Improving cost position in Audiology Improving Division cost and market focus Broadest product portfolio in industry Improved DTC and supplier management Implemented cost control measures Closed business segments, product lines – (including 6% headcount re
Slide 13: Focusing our resources to grow in emerging markets
Focusing our resources to grow in emerging markets Workflow & Solutions revenue growth1) in emerging markets India +9% p.a. FY 2007 FY 2009E Brazil China +12% p.a. +24% p.a. FY 2007 FY 2009E FY 2007 FY 2009E 1) Year-on-year on a comparable basis, i.e. excluding currency translation and portfolio eff
Slide 14: Our products are 'closest to the patient' and services are 'closest to the customer'
Our products are 'closest to the patient' and services are 'closest to the customer' for the Sector Innovative solutions Cross-Sector management driving revenue focused on patient care to divisions Customer Services Radiation Oncology Total Lifecycle Solution for installed base drives revenue to Ima
Slide 15: Customer Services: A recession-resistant business
Customer Services: A recession-resistant business Services across the global Imaging & IT Grew at 2x speed of market in FY 2008 installed customer base #2 position; quickly approaching #1 Customized service agreements Steadily continuous margin increase Customer Service Engineer (CSE) focuse
Slide 16: New Standards of Care (SoC) driving new markets
New Standards of Care (SoC) driving new markets Healthcare trends Creating new markets Increased government scrutiny of, control over Today healthcare costs Pay for performance: Reimbursement tied to Coronary CT in the Emergency Department outcomes not individual services Drive CCTA demand for S
Slide 17: In FY 2008, we presented our first project: Suspected ACS Triage Time
In FY 2008, we presented our first project: Innovate a new Standard of Care for Acute Coronary Syndrome; Create new markets by combining unique Siemens technologies Actual Site Unique enabling technologies ED visits / year High Sens. Troponin I (6 hours reduced to 30 min) 60,000 ADVIA Centaur TnI-Ul
Slide 18: We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome
We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome; driving new business Today Develop automated best practice 1 2 Drive incremental Standards of Care supported business for Siemens by clinical evidence Study: CCTA may reduce length of stay and costs for low-risk pa
Slide 19: We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome
We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome; driving new business Today Develop automated best practice 1 2 Drive incremental Standards of Care supported business for Siemens by clinical evidence From We are driving a new care standard Patients with chest
Slide 20: We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome
We anticipated and supported trend in diagnosis of potential Acute Coronary Syndrome; driving new business Today Develop automated best practice 1 2 Drive incremental Standards of Care supported business for Siemens by clinical evidence From We are driving a new care standard Patients with chest
Slide 21: Stroke: New Standard of Care will drive both biomarker and modality sales
Stroke: New Standard of Care will drive both biomarker and modality sales Mid-term Expanding the therapeutic window in Driving … stroke Increase demand for advanced imaging diagnosis CT now routine – we drive further adoption with best practice consulting MR will become the modality for ultima
Slide 22: Oncology: Integrated workflow in Radiation Therapy will drive add-on sales
Oncology: Integrated workflow in Radiation Therapy will drive add-on sales Long- term Biology modulated radiation therapy Driving PET-CT market … Today, CT is used for every Radiation Therapy patient and is available in every Radiation Therapy treatment center Future: establish CT/PET as a neces
Slide 23: Goal is to leverage our portfolio creating Individualized Standards of Care
Goal is to leverage our portfolio creating Individualized Standards of Care © Siemens AG 2009. All rights reserved. Page 23 Sept. 29, 2009 Capital Market Day Healthcare Healthcare Workflow & Solutions
Slide 24: Goal is to leverage our portfolio creating Individualized Standards of Care
Goal is to leverage our portfolio creating Individualized Standards of Care Precise characterization of disease leads to the most effective care… …and will continue to drive Sector financial returns! © Siemens AG 2009. All rights reserved. Page 24 Sept. 29, 2009 Capital Market Day Healthcare Healthc
Slide 25: Reconciliation and Definitions for Non-GAAP Measures (I)
Reconciliation and Definitions for Non-GAAP Measures (I) To supplement Siemens’ Consolidated Financial Statements presented in accordance with International Financial Reporting Standards, or IFRS, Siemens presents the following supplemental financial measures: New orders; Adjusted or organic gro
Slide 26: Reconciliation and Definitions for Non-GAAP Measures (II)
Reconciliation and Definitions for Non-GAAP Measures (II) Adjusted or organic growth rates of Revenue and new orders In its financial reports, Siemens presents, on a worldwide basis and for each Sector and Cross-Sector Business, the percentage change from period to period in Revenue and new orders a
Slide 27: Reconciliation and Definitions for Non-GAAP Measures (III)
Reconciliation and Definitions for Non-GAAP Measures (III) ROCE at the Siemens group level, on a continuing operations basis Siemens also presents group ROCE on a continuing operations basis. For this purpose, the numerator is Income from continuing operations and the denominator is CE, less Assets
Slide 28: Reconciliation and Definitions for Non-GAAP Measures (IV)
Reconciliation and Definitions for Non-GAAP Measures (IV) Adjusted industrial net debt Siemens defines adjusted industrial net debt as net debt less (1) SFS debt excluding SFS internally purchased receivables; less (2) 50% of the nominal amount of our hybrid bond; plus (3) the funded status of pensi
Slide 29: Siemens investor relations contact data
Siemens investor relations contact data Mariel von Drathen +49-89-636-33780 Munich Office +49-89-636-32474 US Office +1-408-464-2004 Internet: http://www.siemens.com/investorrelations Email: investorrelations@siemens.com Fax: +49-89-636-32830 © Siemens AG 2009. All rights reserved. Healthcare Workfl